About Biomarker Discovery
The Biomarker Discovery category is part of the AI Drug Discovery market map, tracking 13 companies building in this segment. Target discovery, molecular design, protein folding, and clinical trial optimization accelerating the path from lab to patient. Curated by Hartmann Capital's venture research team.
Companies in Biomarker Discovery
- Tempus AI — Public, $2.3B
- Freenome — Series D, $1.4B
- Owkin — Series B, $304M
- Grail — Acquired, $2B
- SOPHiA Genetics — Public, $265M
- PathAI — Series C, $255M
- Veracyte — Public
- Flagship AION Labs — Growth, $60M
- Nference — Series C, $153M
- Promise Bio — Seed, $8M
- NeuroKaire — Series A, $10M
- Aignostics — Series A, $34M
- Foundation Medicine — Acquired
Frequently Asked Questions
- What companies are in the Biomarker Discovery category?
- The Biomarker Discovery category includes 13 companies: Tempus AI, Freenome, Owkin, Grail, SOPHiA Genetics, PathAI, Veracyte, Flagship AION Labs, Nference, Promise Bio, NeuroKaire, Aignostics, Foundation Medicine. This is part of the AI Drug Discovery market map maintained by Hartmann Capital.
- How many Biomarker Discovery startups are tracked?
- Hartmann Capital tracks 13 companies in the Biomarker Discovery segment of the AI Drug Discovery market map.
- What are the best funded Biomarker Discovery companies?
- Top funded companies in Biomarker Discovery include Tempus AI ($2300M), Grail ($2000M), Freenome ($1350M), Owkin ($304M), SOPHiA Genetics ($265M). Browse the full list in the AI Drug Discovery market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.